<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Between 1970 and 1996, 333 patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> underwent HLA-matched related marrow transplant after conditioning with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CY) </plain></SENT>
<SENT sid="1" pm="."><plain>Thirty-five percent of patients transplanted between 1970 and 1976 (group 1), 12% of those transplanted between 1977 and 1981 (group 2), and 9% of patients transplanted between 1982 and 1997 (group 3) had graft rejection </plain></SENT>
<SENT sid="2" pm="."><plain>Graft rejection occurred later among group 3 patients (median, 180 days) than among those in groups 1 and 2 (medians, 28 and 47 days, respectively; P &lt; .001 group 3 v 2) </plain></SENT>
<SENT sid="3" pm="."><plain>In group 3, 92% of rejecting patients underwent a second transplant, compared with 78% and 77% in groups 1 and 2, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Group 1 patients received various conditioning regimens before second transplant, whereas most patients of groups 2 and 3 received CY combined with antithymocyte globulin (ATG) </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">Graft-versus-host disease</z:e> (GVHD) prophylaxis after second transplant consisted of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX) for <z:hpo ids='HP_0000001'>all</z:hpo> group 1 and 2 patients, whereas group 3 patients received MTX combined with <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> (CSP) </plain></SENT>
<SENT sid="6" pm="."><plain>Over the three time periods studied, first graft rejection decreased from 35% to 9%, and the proportion of rejecting patients undergoing second transplants increased from 77% to 92% </plain></SENT>
<SENT sid="7" pm="."><plain>The 10-year probability of survival after second transplants increased from 5% to 83% </plain></SENT>
<SENT sid="8" pm="."><plain>Multivariate analysis showed MTX/CSP GVHD prophylaxis to be a significant factor accounting for the increase in patient survival after second transplant </plain></SENT>
</text></document>